Das Unternehmen

Cerebriu wurde 2018 gegründet.

Wir automatisieren MRT für die Zukunft der diagnostischen Bildgebung, ermöglichen Radiologen, Technologen und Klinikern optimierte Arbeitsabläufe und bringen klinische Intelligenz zum Zeitpunkt der Bildgebung ein.

Vielfalt verbessert
die Kreativität

Nationalitäten

Wissen ist der Schlüssel
zum Erfolg

Personen mit PhD oder MD 

Gemeinsam können wir
mehr erreichen

Mitarbeiter

DIE AUFGABE VON CEREBRIU IST ES, DIE RADIOLOGIE ZU VEREINFACHEN, INDEM WIR KLINISCHE INTELLIGENZ BEI DER MRT BILDGEBUNG EINSETZEN.

Unser Ziel ist es Arbeitsabläufe bei MRT-Scans zu optimieren sodass die richtigen Bildsequenzen, zur richtigen Zeit auf den individuellen Patienten angepasst werden können.

Cerebriu verbessert die Effizienz des Arbeitsablaufs und die Qualität der Versorgung in der diagnostischen Bildgebung, indem es während der MRT-Untersuchung automatisch Protokollanpassungen vorschlägt, kritische Befunde zum Zeitpunkt der Bildgebung erkennt und dem Pflegeteam für eine schnelle radiologische Analyse bietet und somit das Patientenmanagement optimiert.

Der Einsatz der Cerebriu AI-Software kann dazu beitragen das Vertrauen der Techniker und des Pflegepersonals in die Technik zu verbessern und reduziert die Notwendigkeit von Interventionen durch, reduziert dadurch beruflichen Stress, erhöht die Effizienz der MRT-Nutzung und eine Priorisierung kritischer Befunde und führt.

Since 2020 Cerebriu has been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labour, the environment and anti-corruption.

Leitung

Robert Lauritzen

CEO

Internationale Führungskraft im Bereich IT Life Sciences mit mehr als 25 Jahren Managementerfahrung in High-Tech, MedTech, Start-ups und Großunternehmen von Pharma- und IT-Dienstleistern, Aufbau und Management globaler Liefer- und Vertriebsabwicklung in Europa, den USA und Asien

Martin Lillholm, PhD

Chief Operating Officer

Prof. Lillholm is one of the co-founders and specialised in machine learning at the department of computer science at the University of Copenhagen. Martin holds an extensive background in compliance of medical devices, ensuring licenses to operate, regulatory compliance and quality certification. Previously Prof. Lillholm was the Deputy Head of the Department of Computer Science and worked in the industry. He holds a PhD from IT-University of Copenhagen in computer vision and a master’s from the University of Copenhagen.

Akshay Pai, PhD

CTO

Dr. Pai verfügt über mehr als ein Jahrzehnt Erfahrung im Bereich des maschinellen Lernens mit Schwerpunkt auf medizinischer Bildgebung und ist Erfinder mehrerer Patente und Autor oder Co-Autor von mehr als 50 Forschungspublikationen.

Amine Korchi

CMO

Neuroradiologist, practicing radiologist, award-winning researcher and tech savvy entrepreneur driving radiology disruption.

Thomas Olesen

Chief Commercial Officer

Thomas is an international digital health executive with +15 years of experience of successfully commercializing and rapidly growing sales of novel healthcare technologies on behalf of startups and Fortune500, big corporates (Qualcomm life). Thomas spent over 14 years working in Germany and the US.

Kristine Wernerfelt

CFO

+15 years’ experience working with the strategic/CXO agenda across industries in a variety of settings across investment management, management consulting, corporate finance, solution selling.

CEREBRIU IN THE US:

Zac Durant

Vice President of BD

Zac has a strong commercial background managing strategic alliances, marketing strategy and brand development, with a focus on the US market. Previously at leading companies such as GE Healthcare, Zac developed business growth strategies within emerging segments for portfolio expansion. Zac holds a BS in Chemical Engineering and BA in Philosophy from University of Massachusetts Lowell.

UNSER VERWALTUNGSRAT

Peter Savas

–

Präsident des Verwaltungsrates

Über Peter

Mr. Savas brings over 30 years of experience in executive leadership positions across life sciences. He was CEO of Alseres Pharmaceuticals, Inc., Chairman and CEO of Aderis Pharmaceuticals, developer of the Neupro® transdermal patch marketed worldwide to treat Parkinson’s disease and Restless Legs Syndrome and Chairman and CEO of Unisyn, a cGMP contract manufacturer of biologics for clinical trials. Peter also held executive and operating leadership positions with Bristol Myers, Waters, Millipore, Genex and Zymark. With a personal mission for entrepreneurism and pursuing advancement in neurologic science, Peter bridges strategic and operational healthcare experience with broad access to industry, academia, regulatory and capital markets leaders. Peter holds a BS in Chemistry from Syracuse University and is credentialed as a Professional Director by the American College of Corporate Directors.

Dr. Jonathan Gertler

Board member

About Jonathan

Jonathan P. Gertler joined BioVentures Investors in 2019 and is currently a Managing Director. He has over 35 years of scientific, clinical, entrepreneurial, transactional, and investment expertise in both academic medicine and in the life sciences sector. Dr. Gertler is also the co-founder, Managing Partner and CEO of Back Bay Life Science Advisors, a global life science consultancy and advisory group, and founder of three additional healthcare companies.

Homer Pien

PhD

Verwaltungsratsmitglied

About Homer

Homer Pien currently serves on multiple boards, and was most recently SVP and Chief Scientific Officer at Philips for the Precision Diagnosis cluster of businesses, and prior to that Chief Technology Officer for Imaging System, at Philips as well. Before joining Philips in 2012, he was in the Department of Radiology at Massachusetts General Hospital and Harvard Medical School, where he led the Laboratory for Medical Imaging and Computations. Homer was also at two start-ups, one of which was a biotech company he co-founded and served as CEO prior to the company being acquired. Earlier in his career Homer was at MIT Lincoln Lab and Draper Lab. Homer has a PhD in computer science from Northeastern University (Boston, MA), and MS Management from Massachusetts Institute of Technology (Cambridge, MA).

Ulrik Spork

–

Verwaltungsratsmitglied

About

Ulrik Spork is active as Chairman, board member, and advisor in several emerging life-science and MedTech companies as well as two venture/PE funds-of-funds. For over 25 years Ulrik held senior positions in the Novo Group, where he effectively executed Novo Nordisk’s corporate development activities. He also founded and led as Senior/Managing Partner the Venture, Growth Equity, and Principal Investment activities in Novo Holdings A/S. He holds a master’s degree in engineering from Danish Technical University.

Claudia Colciago

PhD

Board member

About

Dr. Claudia Maria Colciago is a Senior Investment Manager in Denmark’s Export and Investment Fund and member of several boards. She previously held positions such as Associate Director at Takeda Digital Ventures. Prior to that, at MTIP she led a $20m+ financing round in Oviva and partook in the first and following investment in other portfolio companies such as Coramaze, Blueprint Genetics, Tyto Care, Lumeon, and Cynerio. She has a Ph.D. in Applied Mathematics from the École Polytechnique fédérale de Lausanne (EPFL), and a post-doc, where she led a proof-of-concept project of a digital health start-up.